CLINICAL TRIALS PROFILE FOR SIMULECT

Biosimilar Clinical Trials for SIMULECT

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04871607 ↗	Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2021-11-01	This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.
NCT04871607 ↗	Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	Recruiting	City of Hope Medical Center	Phase 2	2021-11-01	This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

All Clinical Trials for SIMULECT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00023244 ↗	Steroid Withdrawal in Pediatric Kidney Transplant Recipients	Terminated	Cooperative Clinical Trials in Pediatric Transplantation	Phase 2	2001-01-01	The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday). Graft survival has improved in recent years in children with kidney transplants. One bad side effect of steroid maintenance therapy has been growth retardation. Doctors believe steroids might be safely withdrawn in patients that are receiving other maintenance therapies. If steroids are removed, children might catch up in their growth and also might have fewer side effects of other kinds. This study evaluates whether steroid therapy can be withdrawn in a way that does not increase graft rejection.
NCT00023244 ↗	Steroid Withdrawal in Pediatric Kidney Transplant Recipients	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-01-01	The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday). Graft survival has improved in recent years in children with kidney transplants. One bad side effect of steroid maintenance therapy has been growth retardation. Doctors believe steroids might be safely withdrawn in patients that are receiving other maintenance therapies. If steroids are removed, children might catch up in their growth and also might have fewer side effects of other kinds. This study evaluates whether steroid therapy can be withdrawn in a way that does not increase graft rejection.
NCT00101738 ↗	Freedom Study: Myfortic in Kidney Transplant Patients	Completed	Novartis Pharmaceuticals	Phase 3	2003-03-01	The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
NCT00113269 ↗	Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients	Completed	Astellas Pharma Inc	Phase 4	2005-05-01	The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.

Clinical Trial Conditions for SIMULECT

Condition Name

Condition Name for SIMULECT
Intervention	Trials
Kidney Transplantation	12
Renal Transplantation	4
Liver Transplantation	3
Renal Transplant Rejection	2

Condition MeSH

Condition MeSH for SIMULECT
Intervention	Trials
Kidney Failure, Chronic	5
Renal Insufficiency	3
Leukemia	3
Hodgkin Disease	3

Clinical Trial Locations for SIMULECT

Trials by Country

Trials by Country for SIMULECT
Location	Trials
United States	140
Canada	15
United Kingdom	13
Germany	11
France	9

Trials by US State

Trials by US State for SIMULECT
Location	Trials
California	12
Pennsylvania	9
Illinois	8
Texas	8
Ohio	8

Clinical Trial Progress for SIMULECT

Clinical Trial Phase

Clinical Trial Phase for SIMULECT
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	11
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for SIMULECT
Clinical Trial Phase	Trials
Completed	36
Terminated	7
Unknown status	4

Clinical Trial Sponsors for SIMULECT

Sponsor Name

Sponsor Name for SIMULECT
Sponsor	Trials
Novartis Pharmaceuticals	10
Novartis	8
Astellas Pharma Inc	6

Sponsor Type

Sponsor Type for SIMULECT
Sponsor	Trials
Other	57
Industry	39
NIH	10

SIMULECT Market Analysis and Financial Projection

Last updated: February 7, 2026

What is the Current Status of Clinical Trials for Simulect?

Simulect (basiliximab) is a monoclonal antibody indicated for preventing organ rejection in kidney, liver, and pancreas recipients. The drug’s development and use focus on transplant immunology. As of early 2023, the following clinical trial updates are available:

• Approved Indications: FDA approved for prophylaxis of acute organ rejection in kidney transplants since 1998; expanded to liver and pancreas transplants.
• Ongoing Trials: No recent large-scale Phase 3 trials are publicly listed for new indications. ClinicalTrials.gov shows predominantly observational studies or post-marketing surveillance.
• Recent Results: No significant updates on breakthrough studies or label expansions. The last pivotal trial data date back to early 2010s, supporting its existing label.

What is the Current Market Landscape for Simulect?

Simulect's market is predominantly within transplant medicine, with limited competition due to its targeted use:

• Market Size: Estimated global transplant immunosuppressants market at USD 4 billion in 2022, with basiliximab accounting for roughly 25-30%. The North American segment dominates, representing over 50%.
• Main Competitors:
  • Tacrolimus and Cyclosporine: First-line drugs for transplant rejection prevention.
  • Simulect's niche: Used as induction therapy, often combined with other immunosuppressants.
• Pricing: Approximate wholesale acquisition cost (WAC) in the U.S. is USD 15,000–USD 20,000 per treatment course, depending on the organ transplanted.
• Reimbursement: Covered broadly under Medicare and private insurance, with some restrictions depending on regional policies.

What Are the Market Projections for Simulect Through 2030?

The prospects depend on transplant rates, biosimilar entry, and new therapeutic indications:

Year	Estimated Global Market (USD billion)	Growth Rate	Drivers
2023	1.2	N/A	Stable, mature market
2025	1.4	8%	Incremental adoption, growing transplant numbers
2030	1.8	10%	Emerging markets, potential label extensions

• Transplant Volume Growth: Slight annual increase (~3–5%), primarily in Asia-Pacific and Latin America.
• Biosimilar Competition: Pending approval and commercialization of biosimilars could exert price pressure post-2025.
• Regulatory Trends: No new indications for Simulect are currently under review; potential exists for expanded approved uses in autoimmune diseases, but none are confirmed as of 2023.

What Are the Key Risks and Opportunities?

Risks

• Market Saturation: Established use in transplant centers limits growth.
• Biosimilar Entry: Biosimilars, like those for rituximab, may lower prices and sales.
• Regulatory Delays: New indications risk prolongation of approval processes.

Opportunities

• Expanded Indications: Autoimmune disease therapy (e.g., multiple sclerosis, lupus) remains experimental.
• Regional Expansion: Increasing transplant rates in emerging markets.
• Combination Therapy: Synergies with newer immunosuppressants warrant exploration.

How Does Simulect Compare to Its Competitors?

Parameter	Simulect	Basiliximab Biosimilars	Tacrolimus/Cyclosporine
Approval Year	1998	Pending or in development	1994, 1983
Indications	Kidney, liver, pancreas	Same	Broad, autoimmune, transplant
Price per Course	USD 15,000–USD 20,000	Lower (projected)	USD 2,000–USD 5,000
Administration Route	IV	IV	Oral

What Are the Strategic Considerations for Stakeholders?

• Pharmaceutical companies face limited growth unless new indications or markets are tapped.
• Investors should monitor biosimilar approvals and regional transplant market expansion.
• Healthcare providers may prefer less costly alternatives if biosimilars gain regulatory approval.

Final Summary of Market Outlook

Simulect’s role as an induction agent in organ transplantation remains stable. The market is mature with slow growth expected over the next decade. Biosatitis playouts are probable, and regional expansion offers growth pathways. No immediate pipeline enhancements or new indications are apparent, maintaining its status as a specialized niche therapy.

Key Takeaways

• Simulect has maintained regulatory approval since 1998, with no recent major clinical advances or label expansions.
• The global market for transplant immunosuppressants sits around USD 4 billion, with Simulect accounting for a significant segment.
• Market growth projections are modest (8–10% annually through 2030).
• Biosimilar competition could pressure prices but remains pending approval.
• Expansion into autoimmune indications could present future growth, though no such trials are currently active.

FAQs

1. Will Simulect’s market share decline due to biosimilar entry?
Potentially, if biosimilars are approved and priced lower, market share could decrease. The impact depends on regulatory timing and physician adoption.

2. Are there prospects for new indications for Simulect?
No active trials or regulatory filings for new labels as of early 2023. Future opportunities exist but remain speculative.

3. How significant is regional growth in emerging markets for Simulect?
Growing transplant programs in Asia-Pacific and Latin America could increase demand, supporting regional expansion.

4. What clinical developments could challenge Simulect’s position?
New immunosuppressants with better safety profiles or biosimilars offering similar efficacy at lower cost may affect its use.

5. What is the likelihood of regulatory approval for Simulect biosimilars?
High, given the established biosimilar pathway and recent approvals for similar biologics. Approval timing varies by region.

---

Sources:
[1] ClinicalTrials.gov, 2023
[2] FDA Drug Database, 2023
[3] IQVIA, 2022 Market Reports
[4] Price reports from wholesale catalogs, 2023